Apollo BioPharmaceutics Overview

  • Founded
  • 1992
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Apollo BioPharmaceutics General Information


Developer of drugs that protect brain cells from damage caused by disease, injury and aging. The company's target applications include the treatment of Alzheimer's disease, Parkinson's disease, brain damage resulting from stroke and other age-related diseases and conditions.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Primary Office
  • 1 Kendall Square
  • Building 200, Suite 2200
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Apollo BioPharmaceutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 27-Jun-2001 00.000 Completed Product Development
5. IPO 16-Jun-1997 00.000 000.00 Cancelled
4. Early Stage VC 01-Dec-1996 00000 00.000 Completed Product Development
3. Early Stage VC 01-Jun-1996 00000 00.000 Completed Product Development
2. Early Stage VC 01-May-1995 $475K $516K Completed Product Development
1. Early Stage VC 01-Sep-1992 $41K $41K Completed Product Development
To view Apollo BioPharmaceutics’s complete valuation and funding history, request access »

Apollo BioPharmaceutics Executive Team (6)

Name Title Board Seat Contact Info
John Curry Vice President, Finance, Secretary & Chief Financial Officer
Donald Weise Director
George Masters Director
Theodore Gordon Director
Robert Leonard Vice President, Business Development, Director & Secretary
You’re viewing 5 of 6 executive team members. Get the full list »

Apollo BioPharmaceutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Lumira Ventures Venture Capital Minority 000 0000 000000 0
NeuroScience Partners Venture Capital Minority 000 0000 000000 0
To view Apollo BioPharmaceutics’s complete investors history, request access »